Landmark study sheds new light on the heterogeneity of type 2 diabetes

FHS
May 13, 2024
5:12 pm

A landmark study by the DZD, published in ‘The Lancet Diabetes & Endocrinology’, sheds new light on the heterogeneity of type 2 diabetes.

Stealth Bio gets FDA adcomm for previously rejected ultra-rare disease drug

Seven years after Stealth BioTherapeutics landed a fast track designation from the FDA, the agency has finally agreed to review the company’s application for an

April 9, 2024

How are insurers handling the Alzheimer’s drug Leqembi and related scans?

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to

July 12, 2023

DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE – Biotech Investments

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON

June 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.